One name to keep straight
Thymosin alpha-1 is a chain of 28 amino acids. Thymalfasin is the man-made version with the same sequence. It’s studied as an immune modulator, meaning it can change how immune cells respond. That doesn’t mean your health will improve.
It’s a different molecule from thymulin, with its own findings.
A bigger trial didn’t find a clear survival benefit
In sepsis, the body’s response to an infection threatens life. Earlier research raised hopes for thymosin alpha-1, but the larger 2025 sepsis trial found no clear reduction in deaths over 28 days. It compared the peptide with placebo, a dummy treatment, in adults in hospital.
The trial reported funding from SciClone Pharmaceuticals, which makes thymalfasin under the name Zadaxin. Several authors listed company grants or fees as well. That context belongs with the finding.
This result limits a survival claim in sepsis. It also tells us nothing about whether healthy people will catch fewer colds. A hospital trial can’t answer every question hidden inside “immune support.”
Safety is more than a sore injection site
The literature review reports redness, irritation and discomfort where shots were given. Those study findings don’t settle the risks of every preparation made another way.
FDA also raises concerns about impurities and immune reactions. The body may treat the material as an invader. FDA says it lacks enough information to fully understand the proposed compounded product’s risks.
There’s no U.S. drug label with FDA-reviewed pregnancy or breastfeeding information. The Italian Zadaxin label, as summarized by FDA, rules out use during pregnancy and breastfeeding. It also flags allergies, autoimmune disease and use with other medicines that affect immunity.
FDA’s summary of the Indonesian label warns about use when the immune system is deliberately held down, including after an organ transplant. These are foreign-label cautions, not a checklist for deciding on treatment yourself.
A withdrawn request isn’t an approval
Thymosin alpha-1 has no U.S. FDA approval. FDA’s safety page groups thymosin alpha-1 with withdrawn nominations. Its content is dated April 22, 2026. Safety concerns remain printed beside the name.
Withdrawal doesn’t clear it for compounding or put it into Category 1. FDA doesn’t say when that request was withdrawn. Compounding also leaves a medicine without FDA approval. The access rules and a clinician’s decision still need attention.